Literature DB >> 33871750

Spinal muscular atrophy: state of the art and new therapeutic strategies.

Sonia Messina1,2, Maria Sframeli3, Lorenzo Maggi4, Adele D'Amico5, Claudio Bruno6, Giacomo Comi7,8, Eugenio Mercuri9.   

Abstract

Spinal muscular atrophy (SMA) is a severe disorder of motor neurons and the most frequent cause of genetic mortality, due to respiratory complications. We are facing an exciting era with three available therapeutic options in a disease considered incurable for more than a century. However, the availability of effective approaches has raised up ethical, medical, and financial issues that are routinely faced by the SMA community. Each therapeutic strategy has its weaknesses and strengths and clinicians need to know them to optimize clinical care. In this review, the state of the art and the results and challenges of the new SMA therapeutic strategies are highlighted.

Entities:  

Keywords:  Antisense oligonucleotides; Gene therapy; Nusinersen; Spinal muscular atrophy; Therapy

Year:  2021        PMID: 33871750     DOI: 10.1007/s10072-021-05258-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  46 in total

1.  Genetic risk assessment in carrier testing for spinal muscular atrophy.

Authors:  Shuji Ogino; Debra G B Leonard; Hanna Rennert; Warren J Ewens; Robert B Wilson
Journal:  Am J Med Genet       Date:  2002-07-15

2.  The c.859G>C variant in the SMN2 gene is associated with types II and III SMA and originates from a common ancestor.

Authors:  S Bernal; L Alías; M J Barceló; E Also-Rallo; R Martínez-Hernández; J Gámez; E Guillén-Navarro; J Rosell; I Hernando; F J Rodríguez-Alvarez; S Borrego; J M Millán; C Hernández-Chico; M Baiget; P Fuentes-Prior; E F Tizzano
Journal:  J Med Genet       Date:  2010-06-24       Impact factor: 6.318

3.  Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype.

Authors:  V Dubowitz
Journal:  Eur J Paediatr Neurol       Date:  1999       Impact factor: 3.140

4.  Prenatal onset spinal muscular atrophy.

Authors:  M J MacLeod; J E Taylor; P W Lunt; C G Mathew; S A Robb
Journal:  Eur J Paediatr Neurol       Date:  1999       Impact factor: 3.140

5.  Correlation between severity and SMN protein level in spinal muscular atrophy.

Authors:  S Lefebvre; P Burlet; Q Liu; S Bertrandy; O Clermont; A Munnich; G Dreyfuss; J Melki
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

6.  A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients.

Authors:  K Zerres; S Rudnik-Schöneborn; E Forrest; A Lusakowska; J Borkowska; I Hausmanowa-Petrusewicz
Journal:  J Neurol Sci       Date:  1997-02-27       Impact factor: 3.181

Review 7.  Twenty-Five Years of Spinal Muscular Atrophy Research: From Phenotype to Genotype to Therapy, and What Comes Next.

Authors:  Brunhilde Wirth; Mert Karakaya; Min Jeong Kye; Natalia Mendoza-Ferreira
Journal:  Annu Rev Genomics Hum Genet       Date:  2020-01-31       Impact factor: 8.929

8.  Spinal muscular atrophy: a timely review.

Authors:  Stephen J Kolb; John T Kissel
Journal:  Arch Neurol       Date:  2011-04-11

9.  Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND).

Authors:  Allan M Glanzman; Michael P McDermott; Jacqueline Montes; William B Martens; Jean Flickinger; Susan Riley; Janet Quigley; Sally Dunaway; Jessica O'Hagen; Liyong Deng; Wendy K Chung; Rabi Tawil; Basil T Darras; Michele Yang; Douglas Sproule; Darryl C De Vivo; Petra Kaufmann; Richard S Finkel
Journal:  Pediatr Phys Ther       Date:  2011       Impact factor: 3.049

Review 10.  Longitudinal natural history of type I spinal muscular atrophy: a critical review.

Authors:  Eugenio Mercuri; Simona Lucibello; Marco Perulli; Giorgia Coratti; Roberto de Sanctis; Maria Carmela Pera; Marika Pane; Jacqueline Montes; Darryl C de Vivo; Basil T Darras; Stephen J Kolb; Richard S Finkel
Journal:  Orphanet J Rare Dis       Date:  2020-04-05       Impact factor: 4.123

View more
  3 in total

1.  The influence of tone on proximal femoral and acetabular geometry in neuromuscular hip displacement: A comparison of cerebral palsy and spinal muscular atrophy.

Authors:  Armagan Can Ulusaloglu; Ali Asma; Kenneth J Rogers; Michael Wade Shrader; H Kerr Graham; Jason J Howard
Journal:  J Child Orthop       Date:  2022-04-30       Impact factor: 1.917

Review 2.  Protein Network Analysis Reveals a Functional Connectivity of Dysregulated Processes in ALS and SMA.

Authors:  Sabrina Kubinski; Peter Claus
Journal:  Neurosci Insights       Date:  2022-03-28

Review 3.  Spinal Muscular Atrophy Treatments, Newborn Screening, and the Creation of a Neurogenetics Urgency.

Authors:  Russell J Butterfield
Journal:  Semin Pediatr Neurol       Date:  2021-05-29       Impact factor: 3.042

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.